Episode
2385: MedPal AI on the Road to Breakeven
- Podcast
- The Vox Markets Podcast
- Published
- Apr 29, 2026
- Duration seconds
- 498
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8896856
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2385-medpal-ai-on-the-road-to-breakeven/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2385-medpal-ai-on-the-road-to-breakeven.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Watch on YouTube MedPal AI Plc (AIM: MPAL) has snapped up the Remedi pharmacy assets out of administration for less than half a million pounds — a deal that brings with it an NHS dispensing hub in Runcorn, a care home patient book that historically delivered over £10 million in annualised turnover, and a fleet of BD Rowa robotic dispensing kit. Founder and CEO Jason Drummond joins us to unpack the numbers, explain how the Swaffham reactivation playbook will be re-run at scale across the new patient book, and lay out the path to pharmacy-level EBITDA breakeven at 80,000 items a month — pencilled in for October or November this year. We get into the strategic logic of a north-south footprint, where the execution risks sit, and how today’s deal fits into the bigger MedPal story across MedPal.clinic , Health OS and the at-home blood test business.